Good info thanks. Great news for US division
Printable View
http://www.odt.co.nz/news/business/2...oss-us-beckons
Don't think I'll sell just yet.
Interesting about Predictive Bioscience. I'm picking the difference between their product and CXBladder is that Pacific Edge have done the hard yards in terms of developing their product so they were able to provide catergory one clinical trial data. Good enough to be published in the American Journal Of Urology.
As has been mentioned previously on this thread, medical specialists can be a conservative lot, so getting the science right and providing the proper clinical evidence is essential in launching a new product. There might be some frustration regarding revenue to date, but things look to be on track to me.
All good barney. One thing that concerns me is the fact that they have this name of Pedusa. Bit too much like the mythical Medusa, the young lady with the snake encrusted bad hair day whose countenance could only be observed by using a mirror. However, upon reflection, I suppose the snake is all part of the medical symbol. Just hope it all doesn't become a near myth or a load of old cobras
and with a spare 14.5 million worth of business trying to find a home now it could get very interesting very quickly. If it turns out that PEB has blown the major US opposition out of the water at this stage with a superior test package or at least has something more suitable available then I see them becoming a benchmark in this field worldwide.
[QUOTE=barney;409943]http://www.odt.co.nz/news/business/2...oss-us-beckons
This sounded interesting...
"Mr Darling said Cxbladder had several applications for a number of variations within diagnosing bladder cancer, and the company was in negotiations with several parties, but he was unable to identify them yet."
That was a bit of a suprise Hancocks, 25 staff already with another 14 to be hired in coming months. It just shows how much work they have been doing and how far they have come in a reasonably short time. Hats off to David Darling and co.
Looks like there might be some more announcements coming in the monthe ahead, if negotiations go as planned.
AGM on August 22nd will be an interesting affair. I think they might need a bigger venue this year.
If we were to assume similar market penetration in NZ/AUS.
Yr1: 0.005*55000/85000(total no. of tests,low/high conservative)
=275/425 (market share)
275/425*320(retail cost,NZ)=88000/136000(total sales yr1)
> actual 198000
Yr2: @ 0.02 > 352000/467500 (total sales). > Actual 182000
Yr3. @0.05 > 880000/1360000 (total sales) > 400/700% increase
The early NZ/Aus growth curve is a little different to the US curve IMHO, as PEB have been boldly attempting to sell concurrently with an R&D or pre-approvals development phase up until now.
If you or I were to sit in a senior urologists or a DHB general managers chair and spin around a few times we may very well realise that the last question we would want to receive is 'why we had committed to a CxBladder test programme that ultimately failed US regulatory approval'.
It is entirley possible that what we have been seeing in the second half of the 2013 year is health professionals waiting, waiting, waiting, waiting for CLIA approval, and now it’s been achieved it's now time for them to commit. The lull or anticipation period may be what we are seeing reflected in the local market FY13 sales figures having dropped slightly. And, sure enough we are only now, post CLIA approval, starting to see DHB's come on board.
Agree that the NZ, Australian and Spanish sales will be a nice sweetener on top of the US sales growth curve.
Ahemmm......., should any of the good folk at PEB ever read this thread, you’re most dedicated and loyal investors would like to request quarterly sales reports from here on forward, then we don't have to guess as above - many thanks.